

## **Lecture Overview**

- Introduction to the Organic Acids Test (OAT)
- The OAT for yeast & mold toxin assessment
- The OAT for clostridia & other bacteria toxin assessment.
- The OAT for oxalate assessment
- Neurotransmitter imbalances and mitochondrial function assessment.
- Indicators of other problems: nutrient deficiencies, fatty acid metabolites, etc.



## Prioritization Based On Common Findings

- The OAT can be a complicated test with many markers indicating a variety of potential problems.
- This lecture presentation focuses on what is seen *most* commonly in practice with regards to the OAT.
- The vast majority of OAT's (approximately 80%) that you will see from a variety of patients/clients will have similar patterns.
- Each OAT needs to be applied clinically to the patient/client and treatment not just implemented based on test markers.

## What Is The OAT?

- Organic acids are compounds with acidic properties:
   Carboxyl (-COOH)
  - Alcohol (-OH)
- Thiol (-SH)
- An accurate assessment of what is going on metabolically in the body.
- Evaluates <u>over</u> 70 urinary metabolites that can be useful for discovering underlying causes of chronic illness.
- Treatment based on OAT findings often leads to improved energy, sleep and mental health conditions, as well as reduced attention and concentration problems, chronic pain and digestive problems.

## **GPL OAT Sections**

- Yeast and Fungal Markers:
  - · Evaluates for invasive candida and mold toxicity
- Bacterial Markers:
  - Evaluates for dysbiosis
- Clostridia Bacteria Markers:
- Evaluates for various clostridia bacteria toxins
  Oxalate Metabolites:
- Evaluates for oxalic acid toxicity and endogenous oxalate production problems.
- Glycolytic and Mitochondrial Markers:
   Evaluates for mitochondrial dysfunction

## **GPL OAT Sections**

- Phenylalanine and Tyrosine Metabolites:
   Evaluates for phenylalanine and tyrosine metabolism which can lead to dopamine and norepinephrine imbalances.
- Tryptophan Metabolites:
   Evaluates for issues in tryptophan metabolism which
- contributes to serotonin imbalance and excess quinolinic acid production.
  Pyrimidine Metabolites:
- Evaluates for uracil and thymine as indicators of folate imbalance.

## **GPL OAT Sections**

- Ketone and Fatty Acid Oxidation:
   Evaluates for fatty acid metabolism problems which can
- contribute to mitochondrial dysfunction.
- Nutritional Markers:
  - Evaluates for various nutrient imbalances
- Indicators of Detoxification:
  - $^\circ\,$  Measures organic acids linked to glutathione status

## **GPL OAT Sections**

- Amino Acid Metabolites:
  - Measures organic acids linked to inborn errors of metabolism and other metabolic imbalances.
- Mineral Metabolism:
  - Measures phosphoric acid linked dietary consumption of phosphate (processed foods), as well as bone metabolism and vitamin D status.

## Who Is The Test Beneficial For?

- Autism
- ADD/ADHD
- Autoimmune
- Chronic fatigue
- Digestive problems
- Metabolic disorders
- Mental health disorders
- Neurological disorders

Any individual with a chronic health

condition where you suspect metabolic toxins may be a

causative or contributing factor.



Suggestions For Reviewing An Organic Acids Test

	William Shaw, Ph.D., Dire	ector	11813 We	st 77th	Street	Lenexa, P	5 66214	(913) 341-894	9 Fax (	913) 341-6207	
Requisi	tion A:						Physician:		KURT WOEL	LER DO	
Patient	Nama:						Date of Collect	tion:	3/27/2017		
Patient.	Age: 2						Time of Collect	tion:	03:30 PM		
Patient	Sex: F						Print Date:		04/12/2017		
X		Organ	nic Acio	ls Te	st -	Nutri	tional and	i Metabo	lic Profile	e	
Metab	olic Markers in Urine	Refer (mmotiv	ence Rang nol creatini	30 ne)	F	Patient Value	Ret	ference Popu	lation - Fema	ales Under Age	13
Inte	stinal Microbial Over	growth									
Yeast	and Fungal Markers										
1	Citramalic		5	0.3		4.1				-40-	
2	5-Hydroxymethyl-2-furoic		-	30	н	65		-	<65		
3	3-Oxoglutaric		5	0.52		0	-00-			_	
4	Furan-2,5-dicarboxylic		\$	22		16				(16)	
5	Furancarbonylglycine		5	3.6		0.44	- 040				
6	Tartaric		\$	3.9	н	21		-			21
7	Arabinose		s	56	н	354		-			(6
8	Carboxycitric		5	34		4.9	(4.9	>	_	_	Ť
0	Tricarballulic			0.85		0.12			~		- 1







Ovalue         Unit         Unit <thunit< th="">         Unit         Unit         <!--</th--><th>Meta</th><th>bolic Markers in Urine</th><th>Reference P (mmol/mol cred</th><th>tan st/s</th><th>ge (ne)</th><th>P</th><th>atient /alue</th><th>Reference Popu</th><th>ation - Females Under Age 1</th><th>3</th></thunit<>	Meta	bolic Markers in Urine	Reference P (mmol/mol cred	tan st/s	ge (ne)	P	atient /alue	Reference Popu	ation - Females Under Age 1	3
10     Opende     271     9.5     9.4       20     Opende     20     20     30       11     Oute     12     20     30       50     Opende     20     30     50       50     Opende     50     4     4       20     Particia     8.0     4     4       21     Particia     8.0     4     4       22     Particia     8.0     4     4       23     Particia     8.0     9.0     10       24     Section     50     50     50       25     Opende     51     10     10       26     Opende     51     10     10       27     Opendeation     51     10     10       26     Opende     51     10     10       27     Opendeation     51     10     10       20     Opendeation     51     10     10       27     Opendeation     51     10     10       27     Opendeation     51     10     10       20     Opendeation     51     10     10       20     Opendeation     51     10     10       20	0	alate Metabolites								
a         Openic         20         - 20         30         Openic         - 20         -	19	Glyceric	0.71		9.5		9.4			-
1         Oute         1         I	20	Glycolic	20		202		33	H-30		_
Bijevolytic Cycle Metabolites           21         Intit:         0.01         4.4         4           23         Parrici         0.01         4.4         4           24         Intit:         0.01         4.4         4           25         Parrici         0.01         4.4         4           26         Parrici         0.01         1.5         1.5           27         Parrici         0.01         1.0         1.0           24         Incolor         0.01         1.0         1.0           25         Transit:         0.01         1.0         1.0         1.0           26         Chic :         0.01         0.01         1.0         1.0         1.0           27         Chic :         0.01         0.01         1.0         1.0         1.0         1.0           27         Chic :         0.01         0.01         1.0         1.0         1.0         1.0           20         Chic :         0.01         0.01         1.0         1.0         1.0         1.0         1.0           20         Chic :         0.01         0.01         0.01         1.0         1.0	21	Oxalic	15	-	174	н	346			
22         Letti:         0.0        44         42           23         Provinic         0.0        4         42           43         Provinic         0.0        4         42           44         Provinic         0.0        4         10           45         Provinic         6.0         10         10           26         Provinic         6.0         10         10           27         Aborgination         6.00         10         10           28         Anotics         10         10         10           29         Anotics         11         32         10         10           20         Anotics         11         32         10         10           20         Chits         10         10         10         10	GI	ycolytic Cycle Metabol	ites							
Barrier         Barrier         Control         Control <t< td=""><td>22</td><td>Lactic</td><td>0.18</td><td></td><td>44</td><td></td><td>42</td><td></td><td></td><td>10</td></t<>	22	Lactic	0.18		44		42			10
1         10 </td <td>21</td> <td>Panair</td> <td>0.88</td> <td></td> <td>9.1</td> <td></td> <td>57</td> <td></td> <td></td> <td>10</td>	21	Panair	0.88		9.1		57			10
A         Swelink         6         18         18         20           23         Mark         6.04         -1.3         H         5.6           24         Mark         6.04         -1.3         H         5.6           25         Mark         6.22         H         7.3	M	tochondrial Markers - I	(rebs Cycle Me	tat	olites					
24         Boolesity:         5         10         10         12           25         Function:         0.01         -1.3         H         5.6           26         Matrix:         5.2         H         7.3										
Image:         Date         Solution         S	24	Succinic		s	15	н	123			
24         Mark         5         2         M         7	25	Fumaric	0.04	-	1.3	н	5.6			
27         Decopation         5         11         7	25	Malic		s	2.2	н	7.9			
21         Advite         11         -33         35           20         Cele         80         -44         14         10           Mitochanok/of Mattery - Annon Actif MarkAddina           90         Methyphanek         0.07         -0.55         14         1.0           10         Methyphanek         0.07         -0.55         14         1.0	27	2-Oxoglutario		s	81		8.7	-0>		
20         Cirkie         99         - 440         H         1319           Mitochomośrał Markers - Amino Acid Methodites           30         Jakonowski M         13	28	Aconitic	11		35		35			
Mitochondrial Markers - Amino Acid Metabolites	29	Citrio	59		440	н	1 319			
30 3-Methylphanic 0.07 · 0.95 H 1.8	М	itochondrial Markers -	Amino Acid Me	təl	olites					
	30	3.Methylolutaric	0.07		0.95	н	18			
		A third successful starts		J.			40		(a)	







Meta Pj	bolic Markers in Urine	Reference F (mmol/mol creation) Folate Metaboli	an tin	je ne)	P	Patient Value	Reference	Population - Fema	les Under Age 13	
40	Uracil		s	19		7.2		(1)		
41	Thymine	0.01		0.89		0.37		(3)		_
42 43	3-Hydroxybutyric Acetoacetic		VI VI	4.1 10	H	15 25			25>	
43	4-Hydroxybutyric		2	3.4	н	5.9		(5.9)	<25>	
45	Ethylmalonic		s	4.6	н	12			12	
46	Methylsuccinic		ś	4.3	н	6.5		6.5		
47	Adipic		s	9.7	н	44				
48	Suberic		s	9.5	н	53				
49	Sebacic		s	0.37	н	7.8				

Г



Page 3 – Nutritional Markers Nutritional Markers Vitamin B12 50 Methylmalonic + ≤ 6.2 6.1 Vitamin B6 51 Pyridoxic (B6) ≤ 59 46 Vitamin B5 52 Pantothenic (B5) ≤ 26 H 61 Image: Base of the second Vitamin B2 (Riboflavin) 53 Glutaric + s 1.1 H 3.5 Vitamin C 54 Ascorbic 10 - 200 H 251 285 Vitamin Q10 (CoQ10) 55 3-Hydroxy-3-methylglutaric ● ≤ 101 H 113 Glutathione Precursor and Chelating Agent 56 N-Acetylcysteine (NAC) s 0.41 0 000 Biotin (Vitamin H) 57 Methylcitric + \$ 5.5 1.9 A high value for this marker may indicate a deficiency of this vitamin. 17



















































## Conditions In Which Candida May Be a Factor

- Schizophrenia
- Alzheimer's disease
- Systemic lupus erythematosus (SLE)
- Fibromyalgia
- Chronic fatigue
- syndrome & CFIDS
- HIV infection
- PMSVaginal yeast
- infection

  Multiple sclerosis

ColitisDepression

- Interstitial cystitis
- Seizures
- Irritable bowel
- Cancer

Family Practice © Oxford University Press 2001 Vol. 18, No. 3 Printed in Great Britain

Effectiveness of nystatin in polysymptomatic patients. A randomized, double-blind trial with nystatin versus placebo in general practice

Heiko Santelmann, Even Laerum, Joergen Roennevig<sup>a</sup> and Hans E Fagertun<sup>b</sup>

Santelmann H, Laerum E, Roennevig J and Fagertun HE. Effectiveness of nystatin in polysymptomatic patients. A randomized, double-blind trial with nystatin versus placebo in general practice. *Family Practice* 2001; **18**: 258–265.

In the 116 patients selected by the FRDQ-7 questionnaire, nystatin therapy reduced overall symptoms significantly as compared with placebo, even after correction for sugar- and yeast-free diet.

Nystatin showed the most striking effect for mental, abdominal and urogenital complaints. Since we did not perform microbiological studies in the patients and the positive effect of nystatin may be due to its effect on other fungi, a connection between *C.albicans* and FRD remains unproved.

Nystatin is well known for its antifungal effect on *C.albicans* which is found in all segments of the gastrointestinal tract in 10-80% of humans,<sup>14,15,19</sup> as well as on other yeasts and moulds.

# 95% Predicative of Positive Response to Nystatin SCORE: 0 = none 1 = occsional or mild 2 = frequent or moderately severe 3 = severe or disabling 1. Have you, at any time in your life, taken broad spectrum antibiotics? (0 or 3) 2. Have you taken tetracycline or other broad-spectrum antibiotics for one month or longer? (0 or 3) 3. Are your symptoms worse on damp, muggy days or in moldy places? (0 or 3) 4. Do you crave sugar? (0 or 3) 5. Do you have a feeling of being "drained?" (0, 1, 2 or 3) 6. WOMEN: Are you bothered with vaginal burning, itching or discharge? (0, 1, 2 or 3) 7. Are you bothered by burning, itching or tearing of your eyes? (0, 1, 2 or 3)

## TOTAL SCORE FOR FRDQ-7:



Patient Age:	9					Time of Collection:	09:00 AM	
Patient Sex:	м					Print Date:	05/20/2015	
		Organic A	ids Te	st -	Nutri	tional and Metabo	lic Profile	
Metabolic Mark	ers in Urine	Reference R (mmol/mol creat	ange tinine)	F	Patient Value	Reference Pop	oulation - Males Under Age 13	
Intestinal M	crobial Overg	rowth						
Yeast and Funga 1 Citramalic	Markers		≤ 5.0		1.2	(2)		-
2 5-Hydroxy	methyl-2-furoic		≤ 28	н	491			491
3 3-Oxoglut	aric		≤ 0.46		0	0.00-		
4 Furan-2,5	dicarboxylic		≤ 18	н	51		<u>(51)</u>	
5 Furancart	onylglycine		s 3.1		0.24	-0.24-		-
6 Tartaric			≤ 6.5	н	67			67
7 Arabinosi			≤ 50	н	59	<b>50</b>		



# Clostridia Toxin Assessment

## Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825-834

- The Centers for Disease Control estimates that there were 453,000 documented cases of Clostridium difficile infection (CDI) in the United States in 2011 leading to 29,300 deaths.
- Between 10% and 30% of people who have an initial episode of CDI will develop at least one recurrence.
- On the basis of the number of incident cases found in 2011, 45,300-135,900 people developed recurrent CDI.



## Toxin A & Toxin B

- These two toxins are the main virulence factors related to mucosal damage from C. difficile.
- Toxins A & B lead to digestive tract inflammation, e.g.
   Pseudomembranous colitis or clostridia difficile associated diarrhea (CDAD).



 Toxin A & Toxin B are both capable of causing mucosal damage (Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP; October 2010. "The role of toxin A and toxin B in Clostridium difficile infection". *Nature* 467 (7316): 711–3).





1		Organic Ac	id	s Tes	t-	Nutri	tional and Metabolic Profile	
Met	abolic Markers in Urine	Reference R (mmol/mol crea	ang tini	je ne)	P	atient /alue	Reference Population - Males Under Age 13	
In	ntestinal Microbial Overg	owth						
16	HPHPA (Clostridia marker)		S	220	н	999		99
17	DHPPA (beneficial bacteria)		S	0.59	н	1.2	12	
N	leurotransmitter Metabol	ites						
30	Homovanillic (HVA)	0.49		13	н	16	16	
31	VanillyImandelic (VMA)	0.72		6.4		6.2		-6.2
32	5-Hydroxyindoleacetic (5-HIA	A)	1	11		0.54	0.54	_







<b>*</b>	Organic Acids Tes	t - Nutrit	ional and Metabolic Brofile
Metabolic Markers in Urine	Reference Ranne	Patient	Peterence Reputation - Males Under Age 12
nembolie markers in onlie	(mmol/mol creatinine)	Value	Reference ropulation - males onder Age 15
Intestinal Microbial Overgro	wth		
HPHPA (Clostridia Marker)	≤ 208	99	
4-Cresol (C. difficile)	≤ 75	H 88	<b>—</b> —
DHPPA (Beneficial Bacteria)	≤ 0.38	0.25	
Neurotransmitter Metabol	ites		
32 Homovanillic (HVA) (dopamine)	0.80 - 3.6	H 16	
33 VanillyImandelic (VMA)	0.46 - 3.7	1.4	14
[norepinepinine, epine			

























Requisition #: Patient Name:			Physician Name: Date of Collection:
Metabolic Markers in Urine	Reference Range (mmol/mol creatinine)	Patient Value	Reference Population - Females Under Age 13
Oxalate Metabolites			
18 Glyceric	0.71 - 9.5	H 18	18
19 Glycolic	20 - 202	100	
20 Oxalic	15 - 174	H 483	483
Glycolytic Cycle Metabolites			
21 Lactic	0.18 - 44	H 301	
22 Pyruvic	0.88 - 9.1	9.0	——————————————————————————————————————
23 2-Hydroxybutyric	≤ 2.2	H 3.7	37
			55














"Isolation and characteristics of collagenolytic enzyme produced by Candida albicans" Infect Immun., H. Kaminishi, et.al, 1986 August; 53(2): 312-316.

Collagen makes up a significant percentage (approx. 30%) of all protein in the body.

## Other Diseases/Disorders in Which Oxalate May Play a Role

Arthritis

- Behavior problems in children
- Interstitial cystitis
- Joint pain
- Fibromyalgia
- Heart disease (atherosclerosis, conduction issues)
- Heavy metal toxicity
- Osteoporosis
- Thyroid problems



	Homovanillic (HVA) (dopamine)		VI	14		12	
33	VanillyImandelic (VMA) (norepinephrine, epinephrine)	0.87	•	5.9		4.4	44
34	HVA / VMA Ratio	0.12		3.0		2.9	
35	5-Hydroxyindoleacetic (5-HIAA) (serotonin)		s	7.7		3.7	
36	Quinolinic	0.63		6.7	н	7.7	
37	Kynurenic		¥1	4.1		0.10	
38	Quinolinic / 5-HIAA Ratio	0.04	-	2.2		2.1	
2	Homovanillic (HVA)		≤	14		7.5	
2	Homovanillic (HVA) (dopamine)		≤	14		7.5	
3	VanillyImandelic (VMA) (norepinephrine, epinephrine)	0.87	1	5.9		3.5	
	HVA / VMA Ratio	0.12		3.0		2.1	
4	5-Hydroxyindoleacetic (5-HIAA)		≦	7.7		3.6	(i)
5	(serotonin)			6.7	н	14	<14>
4 5 6	(serotoniń) Quinolinic	0.63					
4 5 6 7	(serotonin) Quinolinic Kynurenic	0.63	≤	4.1		2.4	























22









Mitochondrial Dysfunction Assessment





Mi	tochondrial Markers - Krebs	Cvcle Me	tabo	olites			
24	Succinic		S	5.3	н	5.4	
25	Fumaric		≤	0.49	н	1.0	
26	Malic		≤	1.1		0.85	
27	2-Oxoglutaric		≤	18		18	
28	Aconitic	4.1		23		15	(15)
29	Citric	2.2	·	260	н	594	<b>─</b> ─ (%)
М	itochondrial Markers - Amin	o Acid Me	tabi	olites			
30	3-Methylglutaric	0.02		0.38	н	0.72	612
31	3-Hydroxyglutaric		≤	4.6	н	7.2	(12)























		, inc.	
Requsition #:		Physician Name:	KURT WOELLER DO
Patient Name: Patient Age:	2	Date of Collection:	4/4/2017 05:20 PM
Sex:	F	Print Date:	4/13/2017
yphosate Profile Metabolite	Result ug/g creatinine	Reference Ra	ange
		LLOQ	75th 95th
Glyphosate	11.3	-	
		0.28	19 25



## Supplement Support for Mitochondrial Function *(examples)*

General supplement support and antioxidant therapy can be helpful for mitochondrial issues.

- Examples:
- L-Carnitine helps with fatty acid transport
- CoQ10 (Ubiquinol)
- Thiamine (B1), Pyridoxine (B6), Riboflavin (B2) all support mitochondrial function.
- Antioxidants help to decrease oxidative stress
- 'Mitochondrial Cocktail' combination approach for balanced mitochondrial support, e.g. CoQ10, NADH.





Requisition #: Patient Name:			Physician Name: Date of Collection:
Metabolic Markers in Urine	Reference Range (mmol/mol creatinine)	Patient Value	Reference Population - Females Under Age 13
Oxalate Metabolites			
18 Glyceric	0.71 - 9.5	H 18	
19 Glycolic	20 - 202	100	100
20 Oxalic	15 - 174	H 483	483
Glycolytic Cycle Metaboli	tes		
21 Lactic	0.18 - 44	H 301	301
22 Pyruvic	0.88 - 9.1	9.0	9.0
23 2-Hydroxybutyric	≤ 2.2	H 3.7	37











	ICIO		letabolites
Ketone and Fatty Acid Oxidation			
39 3-Hydroxybutyric	5 4.1	H 26	2
40 Acetoacetic	≦ 10	H 38	3
41 4-Hydroxybutyric	≤ 3.4	0.44	
42 Ethylmalonic	≤ 4.6	4.1	
43 Methylsuccinic	≤ 4.3	2.4	24
44 Adipic	≤ 9.7	2.8	
45 Suberic	≦ 9.5	6.5	6.5
46 Sebacic	≤ 0.37	H 0.46	☐ 446





Ke	tone and Fatty Acid Ox	(mmol/mol creatini	ne)				
41	3-Hydroxybutyric	5	4.1	н	257		25
42	Acetoacetic	≤	10	н	12		Ĩ
43	4-Hydroxybutyric	s	3.4		0.94		-
44	Ethylmalonic	≤	4.6	н	5.5		
45	Methylsuccinic	5	4.3	н	6.4	→ 64	
46	Adipic	5	9.7	н	187		18
47	Suberic	5	9.5	H.	349		4
48	Sebacic	5	0.37	н	1 185		1



Nutritional Markers & Remaining Sections

# Nutritional Markers Indirect: • Methylmalonic acid - vitamin B-12 • Methylcitric acid - biotin • Glutaric and 3-hydroxy-3-methylglutaric - indicators of riboflavin and coenzyme Q-10 deficiency, respectively. Vermin GN (CorN) 5 3-Hydroxy-3-methylglutaric + 5 8 H 313 Image: Definition of the state o









































